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This editorial refers to ‘Indication of long-term endo-
thelial dysfunction after sirolimus-eluting stent implan-
tation’† by S.H. Hofma et al., on page 166
Hofma et al.1 report the presence of abnormal coronary
vasoconstriction to the endothelium-dependent vasodilator
acetylcholine distally to the site of sirolimus-eluting stent
(SES) implantation. The investigators prospectively studied
15 patients undergoing stenting for a single de novo lesion:
nine with a SES and six with a bare metal stent (BMS).
Coronary endothelial function was assessed at baseline and
6 months follow-up. The presence of abnormal coronary
ﬂow reserve or anatomical differences between the groups
was ruled out by the coronary ﬂow response to adenosine
using intracoronary Doppler and by intravascular ultrasound,
respectively. There was signiﬁcantly more distal epicardial
vasoconstriction to acetylcholine in the SES when compared
with the BMS group. The authors concluded that SES might
have an adverse effect on local coronary endothelial func-
tion. The current study compliments a recent report from
Togni et al.2 which demonstrated that exercise-induced
coronary vasomotion is abnormal in segments distal to SES.
Thus, recently two reports in the literature demonstrated
the presence of coronary endothelial dysfunction related
to SES when compared with BMS. However, both studies
assessed coronary endothelial function by a different meth-
odology: the current study testing the receptor-dependent
response to the endothelial-dependent vasodilator acetyl-
choline and, Togni et al.2 using exercise-induced shear
stress and endothelial-dependent vasodilatation.1 Taken
together, these studies imply that the phenomenon of
coronary endothelial dysfunction following SES is more
generalized and not depending on a speciﬁc pathway.
The endothelium is a monolayer of endothelial cells lining
up the lumen of the vascular bed, strategically located
from a mechanical and metabolic point of view, separating
the vascular wall from the circulation and its blood com-
ponents.3 A healthy endothelium regulates vascular tone
and sustains an anti-thrombotic milieu by the secretion of
various substances. They mediate vasodilatation (nitric
oxide), exert anti-inﬂammatory and anti-aggregatory
effects on platelets (prostaglandins) or have anti-coagulant
or ﬁbrinolytic properties (tissue plasminogen activator).
Endothelial dysfunction is characterized by a reduced
secretion of the earlier substances and can be identiﬁed as
paradoxical vasoconstriction to acetylcholine or in response
to exercise. Furthermore, endothelial dysfunction favours a
thrombogenic vascular environment.
There is a growing body of evidence demonstrating that
endothelial dysfunction can be regarded as the most early
stage of the atherosclerosis process and that its presence
is independently associated with future adverse cardiovas-
cular events.3 Bearing this in mind, the studies by Hofma
et al.1 and Togni et al.2 raise two questions. First, what is
the clinical relevance of endothelial dysfunction after SES
implantation? Secondly, what can be done to address this
issue?
To answer these questions, one needs to identify the
potential procedural or drug related mechanisms by which
SES may induce coronary endothelial dysfunction.
First, the regulation of distal vascular tone is depending
on the integrity of the endothelium. Therefore, using
multiple stents covering long segments of the epicardial
vessel may decrease the release of nitric oxide and other
endothelial derived vasodilators downstream resulting in
distal endothelial dysfunction. In the present studies, this
procedural issue cannot be addressed because of the small
number of patients studied.
Secondly, a direct toxic effect of sirolimus on the distal
endothelium cannot be excluded. To address this potential
mechanism, two issues need to be discussed: (1) the way
by which the drug reaches the distal segment and (2) the
drug–endothelium interaction.
The amount of drug on the stent polymer is relatively
small and the majority of the drug is released locally
within a month. Thus, taking into account the washout
by the coronary blood ﬂow, it is unlikely to assume that
sirolimus is reaching and affecting the endothelium distal
to the stent site directly by the main lumen of the coronary
artery. However, as was raised by the authors, an alternative
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pathway may be entertained.1 sirolimus may diffuse locally
into the vessel wall and reach the vasa vasorum. These can
be regarded as a vascular bed running circumstantially and
parallel to the epicardial structure from the ostium of the
vessel to the microcirculation. In the early stages of athero-
sclerosis, a signiﬁcant increase in the density of the vasa
vasorum can be observed.4 A further stepwise increase of
the neovascularization of the vasa vasorum occurs after
the barotrauma of percutaneous intervention.4 It may be
speculated that sirolimus (or potentially any other eluting
drug) diffuses from the vascular wall into the vasa vasorum
and migrates afterwards, reaching the endothelium
beyond the distal stent border. At this stage, the drug
may have a direct or indirect effect on the endothelium.
Endothelial dysfunction is characterized by an imbalance
between endothelial derived vasodilators and vasoconstric-
tors. sirolimus mediates endothelium-dependent vasodilata-
tion in vitro.5 However, sirolimus may also have a direct
effect on the release of potent vasoconstrictors such as
endothelin, tilting the balance in favour of vasoconstric-
tion.5 Moreover, sirolimus directly induces vascular endo-
thelium damage and thrombosis.6
Another mechanism by which sirolimus may cause
endothelial dysfunction is by impairing vascular repair. The
vascular wall and the endothelium in particular undergo a
constant process of injury and repair in response to mecha-
nical and chemical injuries. Emerging evidence suggests that
bone marrow-derived endothelial stem and progenitor cells
contribute to the repair of vascular injury.7 Sirolimus
attenuates the recruitment of leukocytes and progenitor
cells after vascular injury.8 This mechanism partially
explains its effectiveness in reducing restenosis but may
inversely contribute to an impaired vascular repair distal.
Another pathway by which sirolimus may affect vascular
repair is by a decreased production of vascular endothelial
growth factor, which is considered as a major and essential
stimulus for vascular repair.9
This brings us back to the two baseline questions about
the clinical implications of these recent observations.
There is compelling evidence to suggest that the treatment
of de novo coronary stenosis with SESs is highly effective and
associated with a sustained clinical beneﬁt up to 3 years
after device implantation. How can we reconcile the
excellent clinical outcomes with the emerging reports
demonstrating the association between SES and coronary
endothelial dysfunction? At present, from a clinical point
of view, only the issue of SES thrombosis, in particular late
thrombosis has raised concern with the use of SES. Is early
SES thrombosis a potential clinical manifestation of endo-
thelial dysfunction? Clearly, the concept is unlikely but
nevertheless appealing, certainly in the context of SES
thrombosis occurring during exercise. At present, from
large clinical registries or the randomized trials, no detailed
information is available on the clinical circumstances of
early SES thrombosis. It is indeed not impossible that the
mechanisms of SES and BMS thrombosis are totally different.
How to integrate late SES thrombosis in the concept of
endothelial dysfunction? Currently, the answer is unknown as
endothelial function tests have been performed at 6 months
and not beyond, indicating the need for long-term testing.
Patients, treated by SES, who persist with symptoms
or who present with documented ischaemia without angio-
graphic restenosis, might be considered as another potential
clinical manifestation of SES-induced endothelial dysfunc-
tion. However, this phenomenon has not been reported
until present.
In the light of current knowledge, what can be done from
a practical point of view? The beneﬁcial impact of drugs
such as statins or angiotensin-converting enzyme (ACE)
inhibitors on endothelial function in coronary patients is
known for years.10 Moreover, the beneﬁt of statins, in parti-
cular, has been underscored by the recent observation that
their administration preserves coronary endothelial function
in association with the inhibition of the vasa vasorum
neovascularization in experimental atherosclerosis.10 It is
unclear to which extent statins (and/or ACE-inhibitors)
potentially counterbalance SES-induced endothelial dys-
function. Anyway, these drugs are, by recommendation,
part of the pharmacological regimen of the coronary patient.
In conclusion, the association between SES and coronary
endothelial dysfunction should alert us, even if its clinical
relevance remains unclear today. Practically, all patients
treatedbySES require optimal pharmacological secondary pre-
vention. Further clinical research is warranted to investigate
the long-term impact of SES on endothelial function.
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